Stay updated on Ligelizumab in Chronic Urticaria: Efficacy & Safety Clinical Trial
Sign up to get notified when there's something new on the Ligelizumab in Chronic Urticaria: Efficacy & Safety Clinical Trial page.

Latest updates to the Ligelizumab in Chronic Urticaria: Efficacy & Safety Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedA banner about NIH’s terminology transition and related updates is no longer displayed above the 403 error page.SummaryDifference1%

- Check20 days agoChange DetectedThe site footer revision changed from v3.7.2 to v3.8.0, while the study page remains an access-denied error.SummaryDifference0.2%

- Check27 days agoChange DetectedA site-wide NIH banner announces a terminology transition and links to updates and FAQs, stating that agencies are using “Super Intelligence” in place of “Artificial Intelligence” during the transition.SummaryDifference1%

- Check34 days agoChange DetectedThe site revision in the footer changed from v3.7.1 to v3.7.2. The page continues to display a 403 Forbidden error rather than the study record.SummaryDifference0.2%

- Check41 days agoChange DetectedThe footer now identifies the ClinicalTrials.gov site as revision v3.7.1 instead of v3.7.0.SummaryDifference0.2%

- Check61 days agoChange DetectedThe page now displays a 403 Forbidden error and a minimal header, replacing the previously visible study details, locations, and associated documents.SummaryDifference18%

Stay in the know with updates to Ligelizumab in Chronic Urticaria: Efficacy & Safety Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ligelizumab in Chronic Urticaria: Efficacy & Safety Clinical Trial page.